LF

doc. MUDr. Ľubomír Skladaný, PhD.   SK

Email:
lubomir.skladany@upjs.sk
Homepage:
https://www.upjs.sk/LF/zamestnanec/lubomir.skladany
Faculty:
LF UPJŠ - Pavol Jozef Šafárik University in Košice Faculty of Medicine
Department:
2. IK - 2nd Department of Internal Medicine
Office:
MH4O06
Phone:
ORCID ID:
0000-0001-5171-3623
Head II. Internal Medicine Clinic SZU Banská Bystrica (HEGITO). He works as an assistant professor at 2nd Department of Internal Medicine of UPJŠ FM in Košice. Head He teaches students at UPJŠ and SZU. He is one of the leading Slovak hepatologists and gastroenterologists. He is the lead hepatologist of the Transplant Centre. He was heavily involved in launching the liver transplant program. He is a member of major international professional European companies - EASL, ESPEN. He initiated the establishment of a separate hepatology-gastroenterology department and a nephrology department, which provide care for patients before and after liver and kidney transplantation. He is the president of the Slovak Hepatological Society and a regional expert for hepatology.

Higher education and further qualification growth
First degree of higher education:
Slovak Medical University, Bratislava, 1991, Internal Diseases
Second degree of higher education:
Faculty of Medicine, COMENIUS UNIVERSITY BRATISLAVA, 1995, General medicine
Third degree of higher education:
Slovak Medical University, Bratislava, 2002, Internal diseases

Research /art/ teacher profile

Display details  
Profile courses
Internal medicine 3 - General Medicine, I.+II. degree
Internal medicine - Propedeutics - General Medicine, I.+II. degree
Selected publications

Skladaný Ĺ, Žilinčanová D, Žilinčan M, Okapec S, Danček F, Adamcová-Selčanová S, Kukla M, Koller T. Hepatic venous pressure gradient in patients with (compensated and decompensated) advanced chronic liver disease - A comparison of metabolic dysfunction-associated steatotic liver disease with alcohol-associated liver disease: A retrospective view. PLoS One. 2025 Mar 5;20(3):e0317287. doi: 10.1371/journal.pone.0317287. PMID: 40043074; PMCID: PMC11882044.

Graupera I, Thiele M, Castera L, Pera G, Piano S, Sòria A, Fabrellas N, Toran P, Chacon C, Bech KT, Schnefeld HL, Tonon M, Incicco S, Moussy J, Lévy V, Madir A, Kukic S, Jan Havaj D, Adamcova-Selcanova S, Pustjens J, van Kleef LA, Jiménez-Masip A, Pagès L, Zoncapè M, Weber SN, Galle PR, Harris R, Ibáñez-Samaniego L, Morillas RM, Diaz A, Detlefsen S, Serra-Burriel M, Arslanow A, Andersen P, Pich J, Bonfill E, Korenjak M, Fournier-Poizat C, Llorca A, Gourmelon MC, de Koning HJ, Pérez-Guasch M, Thu Ma A, Juanola A, Pose E, Arteaga I, Villesen I, Hansen JK, Calvino V, Gagliardi R, Boutouria B, Pastrovic F, Kujundzic PD, Zilincanova D, Sulejova KK, Rojo D, de Knegt RJ, Melo MD, Torrejón A, Hernández-Ibáñez R, Hoyo J, Muñoz L, López-Martos R, Griffin SJ, Manns M, Karlsen TH, Newsome PN, Kamath PS, Bañares R, Guha IN, Schattenberg JM, Lammert F, Tsochatzis E, Brouwer WP, Pericàs JM, Skladany L, Grgurevic I, Roulot D, Angeli P, Krag A, Caballeria L, Ginès P; LiverScreen Consortium Investigators. Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study. Lancet. 2026 Apr 11;407(10537):1448-1458. doi: 10.1016/S0140-6736(26)00354-5. PMID: 41969010.

Liečba hepatitídy C pomocou trojkombinácie pegylovaného interferónu, inhibítorov proteázy a ribavirínu: analýza súboru 118 pacientov / Svetlana Adamcová-Selčanová ... [et al.]. [Triple combination therapy for chronic hepatitis C with pegylated interferon, protease inhibitors and ribavirin: the analysis of the cohort with 118 patients]. In: Lekársky obzor. - ISSN 0457-4214. - Roč. 54, č. 7-8 (2017), s. 234 - 240. [ADAMCOVÁ-SELČANOVÁ, Svetlana (20%) - SKLADANÝ, Ľubomír (20%) - KRISTIAN, Pavol jr. (20%) - SCHRÉTER, Ivan (20%) - VIRÁG, Ladislav (20%) ]

Skladany L, Selcanova SA, Zilincanova D, Čiefová J, Havaj DJ, Sulejova KK, Kubanek N, Secnik P, Zemlickova J, Koller T, Arab JP. Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study. Hepatol Int. 2026 May 22. doi: 10.1007/s12072-026-11094-4. Epub ahead of print. PMID: 42174362.

Skladaný Ľ, Líška D, Mesiková K, Havaj D, Adamcová-Selčanová S, Šulejová K, Žilinčanová D, Kohout P. Does the change in Liver Frailty Index over the first week of hospitalisation predict mortality in patients with acute-on-chronic liver failure? A prospective cohort study from a Slovak liver centre. BMJ Open. 2025 May 28;15(5):e100171. doi: 10.1136/bmjopen-2025-100171. PMID: 40441763; PMCID: PMC12121596.

Selected projects

The LiverScreen project will include and screen 30.000 people to validate TE as cost-effective and (clinically) feasible screening strategy for liver fibrosis detection in the general population.

Principal Investigar for Slovak Republic

SIRUS Project – Taking Our Liver Seriously: Screening for Liver Disease in the General Population

Principal Investigator for the Slovakia.

LiverAIM: A biomarker-based platform for early diagnosis of chronic liver disease to enable personalized therapy

Principal Investigator for Slovak Republic

Additional information

Further information


LF